Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Quadrimodal Radiological Prediction (Ultrasound, Angiography/Mammography, Magnetic Rsonance Imaging, Positron Emission Tomography-computed Tomgraphy Scan) of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Centre Henri Becquerel
115 participants
May 28, 2025
INTERVENTIONAL
Summary
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
Eligibility
Inclusion Criteria5
- Signed informed consent
- Patient with histologically proven TNBC
- Indication for neo-adjuvant chemo-immunotherapy treatment
- Age between 18 and 75
- Affiliated or beneficiary of a social protection scheme
Exclusion Criteria12
- Pregnant or breast-feeding women
- Contraindication to immunotherapy
- Inflammatory breast cancer (T4d)
- Metastatic patients
- Allergies to iodine or gadolinium
- Patient with an augmentation prosthesis (for angiography/mammography)
- Claustrophobic patients
- Renal contraindication to contrast products according to SFR-CIRTACI
- Ferromagnetic material
- Uncontrolled diabetes (blood glucose \>10 mmol/L)
- Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).
- Patient under guardianship, curatorship or safeguard of justice
Interventions
The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06879704